^
Association details:
| Biomarker: | QKI-RAF1 fusion |
|---|---|
| Cancer: | Spindle Cell Sarcoma |
| Drug: | temozolomide (DNA synthesis inhibitor) + irinotecan (Topoisomerase I inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Sustained Response to the Mitogen-Activated Extracellular Kinase Inhibitor Trametinib in a Spindle Cell Sarcoma Harboring a QKI-RAF1 Gene Fusion
Published date:
01/20/2022
Excerpt:
...a case of recently described spindle cell tumor displaying a QKI-RAF1 gene fusion resistant to standard cytotoxic chemotherapy. The patient was treated with temozolomide-irinotecan as second-line chemotherapy. This treatment was poorly tolerated, and the tumor size increased on MRI after one cycle.
DOI:
10.1200/PO.21.00303 JCO Precision Oncology
